Helixmith Co., Ltd (KOSDAQ:084990)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 108.67B |
| Revenue (ttm) | 4.97B |
| Net Income (ttm) | -15.47B |
| Shares Out | 46.05M |
| EPS (ttm) | -329.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,347 |
| Average Volume | 158,923 |
| Open | 2,360.00 |
| Previous Close | 2,405.00 |
| Day's Range | 2,335.00 - 2,455.00 |
| 52-Week Range | 2,225.00 - 4,950.00 |
| Beta | 1.05 |
| RSI | 44.25 |
| Earnings Date | Mar 21, 2025 |
About Helixmith
Helixmith Co., Ltd develops biologic and natural nutraceutical products. The company offers LAYLA Tab for osteoarthritis; Allex and Allex i for hypersensitivity improvement; and Mnemosyne for memory improvement. Its lead gene therapy product is Engensis (VM202), which is in a phase III clinical trial for diabetic peripheral neuropathy and diabetic foot ulcer; a phase II clinical trial for amyotrophic lateral sclerosis (ALS) and claudication; and a phase I clinical trial for charcot-marie-tooth disease and coronary artery disease. The company al... [Read more]
Financial Performance
In 2024, Helixmith's revenue was 4.97 billion, an increase of 18.38% compared to the previous year's 4.20 billion. Losses were -15.47 billion, -75.86% less than in 2023.
Financial StatementsNews
Price Over Earnings Overview: Vipshop Holdings
In the current market session, Vipshop Holdings Inc. (NYSE: VIPS) share price is at $13.85, after a 4.09% decrease. Over the past month, the stock increased by 13.78% , but over the past year, it act...